NEW YORK (GenomeWeb) – A trial in the UK of Beckman Coulter's CE-marked molecular diagnostics system, the DxN Veris, has demonstrated enhancements to workflow and productivity.
In the analysis, published in the August issue of Pathology in Practice, laboratorians at the Department of Virology at Sheffield Teaching Hospitals NHS Foundation Trust examined the effect of consolidating four virology assays onto the DxN Veris.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
